[1]于 帆,楼 爽,韦 唯,等.基于生物信息学分析POFUT1 表达与肿瘤免疫浸润水平及患者预后的相关性研究[J].现代检验医学杂志,2024,39(02):81-85+174.[doi:10.3969/j.issn.1671-7414.2024.02.015]
　YU Fan,LOU Shuang,WEI Wei,et al.Study on Correlation between Expression Level of POFUT1 and Tumor Immune Infiltration Level and Patient Prognosis Based on Bioinformatics Analysis[J].Journal of Modern Laboratory Medicine,2024,39(02):81-85+174.[doi:10.3969/j.issn.1671-7414.2024.02.015]
点击复制

基于生物信息学分析POFUT1 表达与肿瘤免疫浸润水平及患者预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第39卷
期数:
2024年02期
页码:
81-85+174
栏目:
论著
出版日期:
2024-03-31

文章信息/Info

Title:
Study on Correlation between Expression Level of POFUT1 and Tumor Immune Infiltration Level and Patient Prognosis Based on Bioinformatics Analysis
文章编号:
1671-7414（2024）02-081-06
作者:
于 帆; 楼 爽; 韦 唯; 周义文
（南方医科大学深圳医院临床检验医学中心，广东深圳 518000）
Author(s):
YU Fan;  LOU Shuang;  WEI Wei;  ZHOU Yiwen
（Clinical Laboratory Medical Center, Shenzhen Hospital of Southern Medical University, Guangdong Shenzhen 518000, China）
关键词:
蛋白-O- 岩藻糖基转移酶1; 肿瘤免疫微环境; 免疫浸润; 泛癌分析
分类号:
R730.43
DOI:
10.3969/j.issn.1671-7414.2024.02.015
文献标志码:
A
摘要:
目的　分析蛋白-O- 岩藻糖基转移酶1（protein O-fucosyltransferase 1，POFUT1）表达与肿瘤免疫浸润水平及患者预后的关系，探索POFUT1 在肿瘤免疫治疗方面的价值。方法　基于泛癌数据利用R 软件分析各类肿瘤组织中POFUT1 表达水平变化及其与各类肿瘤患者风险比的相关性，筛选患者预后与POFUT1 表达相关的肿瘤类型；利用String 数据库构建蛋白质互作网络，筛选以POFUT1 关联基因并进行功能富集分析；利用estimate 包分析所筛选肿瘤组织POFUT1 表达与免疫浸润评分的相关性；利用TIMER 数据库分析肿瘤组织POFUT1 表达与各类免疫细胞浸润水平的相关性及免疫细胞浸润水平与患者预后的相关性。结果　POFUT1 在14 类肿瘤中的高水平表达差异具有统计学意义（均P<0.05），与低级别胶质瘤、肺腺癌、甲状腺癌的不良预后相关（Hazard Ratio>1，P<0.05）；POFUT1 及其关联基因高度参与Notch 信号通路、淋巴细胞激活及免疫过程调控进程；POFUT1 表达水平与低级别胶质瘤中的B 细胞、CD8+T细胞、CD4+T 细胞、巨噬细胞、中性粒细胞与树突状细胞、肺腺癌中的中性粒细胞、甲状腺癌中的B 细胞、CD4+T 细胞及巨噬细胞的浸润程度均呈正相关（|r|>0.2，P<0.05）；上述6 类免疫细胞高浸润程度均与低级别胶质瘤患者较差的预后相关（Hazard Ratio>1，P<0.05）。结论　POFUT1 通过对免疫调控相关进程的高度参与，对部分肿瘤免疫浸润水平产生影响并影响患者预后，具有成为免疫治疗靶点的潜力。
Abstract:
Objective　To analyze the relationship between expression level of protein O-fucosyltransferase 1 (POFUT1) and tumor immune infiltration level and prognosis of patients, and explore the value of POFUT1 in tumor immunotherapy. Methods　 Based on the pan-cancer data, R software was used to analyze the changes in POFUT1 expression levels of various tumor tissues and their correlation with the risk ratio of various tumor patients, and screen for tumor types related to patient prognosis and POFUT1 expression. Through the String database, a protein interaction network was constructed, POFUT1-associated genes were screened, and functional enrichment analysis was performed. The estimate software package was used to analyze the correlation between POFUT1 expression and immune infiltration score in selected tumor tissues. The TIMER database was used to analyze the correlation between the expression level of POFUT1 and various levels of immune cell infiltration, and the correlation between the infiltration level of immune cells and the prognosis of patients. Results　The expression levels of POFUT1 were significantly high in 14 types of tumors (P<0.05), and were associated with poor prognosis of low-grade gliomas, lung adenocarcinoma, and thyroid cancer (Hazard Ratio>1, P<0.05). POFUT1 and its associated genes were highly involved in Notch signaling pathway, lymphocyte activation and immune regulation processes. The expression level of POFUT1 was positively correlated with the infiltration degree of B cells, CD8+T cells, CD4+T cells, macrophages, neutrophils and dendritic cells in lowgrade gliomas, as well as positively associated with the infiltration level of neutrophils in LUAD, and B cells, CD4+ T cells and macrophages in thyroid cancer (|r|>0.2, P<0.05). The high infiltration levels of the above 6 types of immune cells were correlated with the poor prognosis of patients with low-grade glioma (Hazard Ratio>1, P< 0 . 0 5 ) . Conclusion POFUT1 was highly involved in the process of immune regulation, affecting the immune infiltration level of some tumors and further influencing patient prognosis. It may have the potential to become a target for tumor immunotherapy.

参考文献/References:

[1] SIEGEL R L, MILLER K D, JEMAL A. Cancer statistics, 2019[J]. CA-A Cancer Journal for Clinicians,2019, 69(1): 7-34.
[2] PANJWANI A A, AGUIAR S, GASCON B, et al. Biomarker opportunities in the treatment of cancerrelated depression[J]. Trends in Molecular Medicine,2022, 28(12): 1050-1069.
[3] WALK E E, YOHE S L, BECKMAN A, et al. The cancer immunotherapy biomarker testing landscape[J].Archives of Pathology & Laboratory Medicine, 2020,144(6): 706-724.
[4] KOMOR M A, DE WIT M, VAN DEN BERG J, et al. Molecular characterization of colorectal adenomas reveals POFUT1 as a candidate driver of tumor progression[J]. International Journal of Cancer, 2020,146(7): 1979-1992.
[5] WAHBY S, JARCZYK J, FIEREK A, et al. POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer[J].Translational Oncology, 2021, 14(1): 100900.
[6] LI Qi, WANG Jia, MA Xudong, et al. POFUT1 acts as a tumor promoter in glioblastoma by enhancing the activation of Notch signaling[J]. Journal of Bioenergetics and Biomembranes, 2021, 53(5): 621-632.
[7] PIAWAH S, VENOOK A P. Targeted therapy for colorectal cancer metastases: a review of current methods of molecularly targeted therapy and the use of tumor biomarkers in the treatment of metastatic colorectal cancer[J]. Cancer, 2019, 125(23): 4139-4147.
[8] DESCHUYTER M, PENNARUBIA F, PINAULT E,et al. Functional characterization of POFUT1 variants associated with colorectal cancer[J]. Cancers, 2020,12(6): 1430.
[9] LI Xinxin, YAN Xianchun, WANG Yufeng, et al. The notch signaling pathway: a potential target for cancer immunotherapy[J]. Journal of Hematology & Oncology,2023, 16(1): 45.
[10] ZHANG Kai, HONG Xiaohua, SONG Zhengbo, et al. Identification of deleterious NOTCH mutation as novel predictor to efficacious immunotherapy in NSCLC[J].Clinical Cancer Research, 2020, 26(14): 3649-3661.
[11] REN Xianwen, ZHANG Lei, ZHANG Yuanyuan, et al. Insights gained from single-cell analysis of immune cells in the tumor microenvironment[J]. Annual Review of Immunology, 2021, 39: 583-609.
[12] DIECI M V, MIGLIETTA F, GUARNERI V. Immune infiltrates in breast cancer: recent updates and clinical implications[J]. Cells, 2021, 10(2): 223.
[13] KIM S I, CASSELLA C R, BYRNE K T. Tumor burden and immunotherapy: impact on immune infiltration and therapeutic outcomes[J]. Frontiers in Immunology,2020, 11: 629722.
[14] WANG Shuhang, SUN Jingwei, CHEN Kun, et al. Perspectives of tumor-infiltrating lymphocyte treatment in solid tumors[J]. BMC Medicine, 2021, 19(1): 140.
[15] NING Shipeng, WU Jianbin, PAN You, et al. Identification of CD4+ conventional T cells-related lncRNA signature to improve the prediction of prognosis and immunotherapy response in breast cancer[J]. Frontiers in Immunology, 2022, 13: 880769.
[16] HUANG Di, CHEN Xueman, ZENG Xin, et al. Targeting regulator of G protein signaling 1 in tumorspecific T cells enhances their trafficking to breast cancer[J]. Nature Immunology, 2021, 22(7): 865-879.
[17] SHI Yu, PING Yifang, ZHOU Wenchao, et al. Tumourassociated macrophages secrete pleiotrophin to promote PTPRZ1 signalling in glioblastoma stem cells for tumour growth[J]. Nature Communications, 2017, 8:15080.
[18] CHRISTOFIDES A, STRAUSS L, YEO A, et al. The complex role of tumor-infiltrating macrophages[J].Nature Immunology, 2022, 23(8): 1148-1156.
[19] PAN Yueyun, YU Yinda, WANG Xiaojian, et al. Tumor-associated macrophages in tumor immunity[J].Frontiers in Immunology, 2020, 11: 583084.
[20] WANG Cheng, MA Cheng, GONG Lihong, et al. Macrophage polarization and its role in liver disease[J].Frontiers in Immunology, 2021, 12: 803037.
[21] DALLAVALASA S, BEERAKA N M, BASAVARAJU C G, et al. The role of tumor associated macrophages (TAMs) in cancer progression, chemoresistance,angiogenesis and metastasis - current status[J]. Current Medicinal Chemistry, 2021, 28(39): 8203-8236.

相似文献/References:

[1]苗 毅a,杨淑梅a,王 晶b,等.肺腺癌组织中MCM4 的表达及其与预后、免疫微环境的相关性分析[J].现代检验医学杂志,2023,38(05):115.[doi:10.3969/j.issn.1671-7414.2023.05.022]
　MIAO Yia,YANG Shumeia,WANG Jingb,et al.Expression of MCM4 in Lung Adenocarcinoma and Its Correlation with Prognosis and Immune Microenvironment[J].Journal of Modern Laboratory Medicine,2023,38(02):115.[doi:10.3969/j.issn.1671-7414.2023.05.022]
[2]刘 捷,杨玲玲,程秋霞,等.非小细胞肺癌患者血清miR-873和miR-138-5p表达水平及其与免疫微环境及预后的相关性分析[J].现代检验医学杂志,2024,39(01):23.[doi:10.3969/j.issn.1671-7414.2024.01.005]
　LIU Jie,YANG Lingling,CHENG Qiuxia,et al.Analysis of the Relationship between Serum miR-873 and miR-138-5p Expression and Immune Microenvironment and Prognosis in Patients with Non-small Cell Lung Cancer[J].Journal of Modern Laboratory Medicine,2024,39(02):23.[doi:10.3969/j.issn.1671-7414.2024.01.005]

备注/Memo

备注/Memo:
基金信息： 吴阶平医学基金会- 临床科研专项资助基金（320.6750.2021-06-30）：基于细胞SELEX 技术的膜受体ROBO1 核酸适配体的筛选鉴定及其在胃癌靶向治疗方向的初步应用研究；南方医科大学深圳医院“后三甲”科研基金（22H3AZF05）：结合多组学分析研究POFUT1 对肿瘤免疫微环境的调控及其机制。
作者简介：于帆（1996-），男，硕士研究生，主管技师，主要从事临床检验诊断学及生物信息学，Email: ninja_yu@outlook.com。
通讯作者：周义文（1965-），男，博士研究生，主任技师，主要从事临床检验诊断学及分子生物学，Email: yiwenzhou21@aliyun.com。
更新日期/Last Update: 2024-03-15